德勤：2020年全球生命科学行业展望报告-创造全新价值,筑就未来发展（英文版）（64页）.pdf

1、2020 global life sciences outlook Creating new value, building blocks for the future Greg Reh | Greg Reh is the Deloitte Global Life Sciences rare diseases, previously believed to be incurable, are on the precipice of real cures.1 Artificial intelligence (AI) and machine learning approaches are rais

2、ing expectations that therapy discovery and development may not only be more innovative, but also more time- and cost-effective. Data-driven approaches have the potential to create value across manufacturing, the supply chain, and the entire health care ecosystem. As technology and behavioral scienc

3、e converge, the focus is increasingly shifting to disease prevention.2 Consumer wearables now have medical-grade sensors,3 and telemedicine, remote monitoring, and virtual trials are reducing complexity for patients.4 Medical algorithms and connected devices are delivering data everywhere.5 In 2020,

4、 biopharma and medtech organizations will be looking for new ways to create value and new metrics to make sense of all the data. As patient-centric models have been adopted within the industry, they are now informing operational approaches and setting the foundation of personalized health care.6 The

5、 human experiences of patients, the workforce, and ecosystem partnersare interrelated and affect business outcomes. With the goal of creating value for all stakeholders, organizations can aspire to find real value for themselves and their shareholders in the coming year. 2020 global life sciences ou

6、tlook 3 “It would be wonderful if we could have a common framework that applies across customer, partner, and workforce. If there is a common way to think about experience across all three parts of the ecosystem, this could drive an enterprises competitive advantage.”13 Creating new value T O PREPAR